Ovarian Carcinogenesis

The Ovary: Second Edition

Volumn , Issue , 2004, Pages 591-612

  Vanderhyden, Barbara C ^a   Shaw, Tanya J ^a   Garson, Kenneth ^a   Tonary, Angela M ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4143063321     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012444562-8/50037-9     Document Type: Chapter

References (266)

1. Murdoch W.J. Ovarian surface epithelium, ovulation and carcinogenesis. Biol. Rev. Camb. Philos. Soc. 1996, 71:529-543.
2. Weiss N.S., Homonchuk T., Young J.L.J. Incidence of the histologic types of ovarian cancer: The U.S. Third National Cancer Survey, 1969-1971. Gynecol. Oncol. 1977, 5:161-167.
3. Papadaki L., Beilby J.O. The fine structure of the surface epithelium of the human ovary. J. Cell Sci. 1971, 8:445-465.
4. Blaustein A., Lee H. Surface cells of the ovary and pelvic peritoneum: A histochemical and ultrastructure comparison. Gynecol. Oncol. 1979, 8:34-43.
5. Moore K.L. The pelvis and perineum. Clinically oriented anatomy 1992, 281-289. Williams & Williams, Baltimore. T.S. Satterfield, L. Napora, K. Lumpkin (Eds.).
6. Espey L.L. Ultrastructure of the apex of the rabbit graafian follicle during the ovulatory process. Endocrinology 1967, 81:267-276.
7. Ribeiro A.F., Ferronha M.H., David-Ferreira J.F. Freeze-fracture study of the hamster ovary surface epithelium intercellular junctions. J. Submicrosc. Cytol. 1983, 15:415-423.
8. Perez R.P., Godwin A.K., Hamilton T.C., Ozols R.F. Ovarian cancer biology. Semin. Oncol. 1991, 18:186-204.
9. Auersperg N., Maines-Bandiera S.L. Culture and characterization of human ovarian surface epithelium. Ovarian Cancer: Methods and Protocols 2000, 169-173. Humana Press. J.M.S. Bertlett (Ed.).
10. Ivarsson K., Sundfeldt K., Brännström M., Janson P.O. Production of steroids by human ovarian surface epithelial cells in culture: Possible role of progesterone as growth inhibitor. Gynecol. Oncol. 2001, 82:116-121.
11. Benjamin E., Law S., Bobrow L.G. Intermediate filaments cytokeratin and vimentin in ovarian sex cordstromal tumours with correlative studies in adult and fetal ovaries. J. Pathol. 1987, 152:253-263.
12. Isola J., Kallioniemi O.P., Korte J.M., Wahlstrom T., Aine R., Helle M., Helin H. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J. Pathol. 1990, 162:295-301.
13. Czernobilsky B., Moll R., Levy R., Franke W.W. Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur. J. Cell Biol. 1985, 37:175-190.
14. Jindal S.K., Ishii E., Letarte M., Vera S., Teerds K., Dorrington J.H. Regulation of transforming growth factor-α gene expression in an ovarian surface epithelial cell line derived from a human carcinoma. Biol. Reprod. 1995, 52:1027-1037.
15. Rodriguez G.C., Berchuck A., Whitaker R.S., Schlossman D., Clarke-Pearson D.L., Bast R.C.J. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am. J. Obstet. Gynecol. 1991, 164:745-750.
16. Miettinen M., Lehto V.P., Virtanen I. Expression of intermediate filaments in normal ovaries and ovarian epithelial, sex cord-stromal, and germinal tumors. Int. J. Gynecol. Pathol. 1983, 2:64-71.
17. Nicosia S.V., Johnson J.H. Surface morphology of ovarian mesothelium (surface epithelium) and of other pelvic and extrapelvic mesothelial sites in the rabbit. Int. J. Gynecol. Pathol. 1984, 3:249-260.
18. Blaustein A., Kaganowicz A., Wells J. Tumor markers in inclusion cysts of the ovary. Cancer 1982, 49:722-726.
19. van Niekerk C.C., Boerman O.C., Ramaekers F.C., Poels L.G. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas. Am. J. Pathol. 1991, 138:455-463.
20. Zeimet A.G., Offner F.A., Muller-Holzner E., Widschwendter M., Abendstein B., Fuith L.C., Daxenbichler G., Marth C. Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125. Tumour Biol. 1998, 19:275-282.
21. Nicosia S.V., Nicosia R.F. Neoplasms of the ovarain mesothelium. Path of Human Neoplasms 1988, 435-486. Raven Press, New York. H.A. Azar (Ed.).
22. Jacobs I., Bast R.C. The CA 125 tumour-associated antigen: A review of the literature. Hum. Reprod. 1989, 4:1-12.
23. Kabawat S.E., Bast R.C., Bhan A.K., Welch W.R., Knapp R.C., Colvin R.B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int. J. Gynecol. Pathol. 1983, 2:275-285.
24. Bjersing L., Cajander S. Ovulation and the mechanism of follicle rupture. V. Ultrastructure of tunica albuginea and theca externa of rabbit graafian follicles prior to induced ovulation. Cell Tissue Res. 1974, 153:15-30.
25. Ackerman R.C., Murdoch W.J. Prostaglandin-induced apoptosis of ovarian surface epithelial cells. Prostaglandins 1993, 45:475-485.
26. Osterholzer H.O., Johnson J.H., Nicosia S.V. An autoradiographic study of rabbit ovarian surface epithelium before and after ovulation. Biol. Reprod. 1985, 33:729-738.
27. Kruk P.A., Auersperg N. Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix. Am. J. Obstet. Gynecol. 1992, 167:1437-1443.
28. Kruk P.A., Uitto V.J., Firth J.D., Dedhar S., Auersperg N. Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. Exp. Cell Res. 1994, 215:97-108.
29. Gillett W.R., Mitchell A., Hurst P.R. A scanning electron microscopic study of the human ovarian surface epithelium: Characterization of two cell types. Hum. Reprod. 1991, 6:645-650.
30. Nicosia S.V. The aging ovary. Med. Clin. North Am. 1987, 71:1-9.
31. Hamilton T.C. Ovarian cancer, Part I: Biology. Curr. Probl. Cancer 1992, 16:1-57.
32. Blaustein A. Surface cells and inclusion cysts in fetal ovaries. Gynecol. Oncol. 1981, 12:222-233.
33. Blaustein A., Kantius M., Kaganowicz A., Pervez N., Wells J. Inclusions in ovaries of females aged day 1-30 years. Int. J. Gynecol. Pathol. 1982, 1:145-153.
34. Deligdisch L., Gil J. Characterization of ovarian dysplasia by interactive morphometry. Cancer 1989, 63:748-755.
35. Bell D.A., Scully R.E. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994, 73:1859-1864.
36. Scully R.E. Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int. J. Gynaecol. Obstet. 1995, 49:S9-S15. (Suppl).
37. Mittal K.R., Zeleniuch-Jacquotte A., Cooper J.L., Demopoulos R.I. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int. J. Gynecol. Pathol. 1993, 12:59-63.
38. Resta L., Russo S., Colucci G.A., Prat J. Morphologic precursors of ovarian epithelial tumors. Obstet. Gynecol. 1993, 82:181-186.
39. Jacobs I.J., Kohler M.F., Wiseman R.W., Marks J.R., Whitaker R., Kerns B.A., Humphrey P., Berchuck A., Ponder B.A., Bast R.C.J. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J. Natl. Cancer Inst. 1992, 84:1793-1798.
40. Mok C.H., Tsao S.W., Knapp R.C., Fishbaugh P.M., Lau C.C. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res. 1992, 52:5119-5122.
41. Scully R.E., Young R.H., Clement P.B. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament 1996, Armed Forces Institute of Pathology, Washington, DC.
42. Fathalla M.F. Incessant ovulation: A factor in ovarian neoplasia?. Lancet 1971, 2:163.
43. Fredrickson T.N. Ovarian tumors of the hen. Environ. Health Perspect. 1987, 73:35-51.
44. Whittemore A.S., Harris R., Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am. J. Epidemiol. 1992, 136:1212-1220.
45. La Vecchia C., Franceschi S. Oral contraceptives and ovarian cancer. Eur. J. Cancer Prev. 1999, 8:297-304.
46. Burmeister L., Healy D.L. Ovarian cancer in infertility patients. Ann. Med. 1998, 30:525-528.
47. Murdoch W.J., Townsend R.S., McDonnel A.C. Ovulation-induced DNA damage in ovarian surface epithelial cells of ewes: Prospective regulatory mechanisms of repair/survival and apoptosis. Biol. Reprod. 2001, 65:1417-1424.
48. Godwin A.K., Testa J.R., Handel L.M., Liu Z., Vanderveer L.A., Tracey P.A., Hamilton T.C. Spontaneous transformation of rat ovarian surface epithelial cells: Association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J. Natl. Cancer Inst. 1992, 84:592-601.
49. Roby K.F., Taylor C.C., Sweetwood J.P., Cheng Y., Pace J.L., Tawfik O., Persons D.L., Smith P.G., Terranova P.F. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000, 21:585-591.
50. Clow O.L., Hurst P.R., Fleming J.S. Changes in the mouse ovarian surface epithelium with age and ovulation number. Mol. Cell Endocrinol. 2002, 191:105-111.
51. Miettinen P.J., Ebner R., Lopez A.R., Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. J. Cell Biol. 1994, 127:2021-2036.
52. Salazar H., Godwin A.K., Daly M.B., Laub P.B., Hogan W.M., Rosenblum N., Boente M.P., Lynch H.T., Hamilton T.C. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst. 1996, 88:1810-1820.
53. Silvester L.M., Luck M.R. Distribution of extracellular matrix components in the developing ruminant corpus luteum: A wound repair hypothesis for luteinization. J. Reprod. Fertil. 1999, 116:187-198.
54. Capo-Chichi C.D., Smith E.R., Yang D.H., Roland I.H., Vanderveer L., Cohen C., Hamilton T.C., Godwin A.K., Xu X.X. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer 2002, 95:1802-1815.
55. Cramer D.W., Welch W.R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl. Cancer Inst. 1983, 71:717-721.
56. Sell A., Bertelsen K., Andersen J.E., Stroyer I., Panduro J. Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol. Oncol. 1990, 37:367-373.
57. Chakravarti S., Collins W.P., Forecast J.D., Newton J.R., Oram D.H., Studd J.W. Hormonal profiles after the menopause. Br. Med. J. 1976, 2:784-787.
58. Scaglia H., Medina M., Pinto-Ferreira A.L., Vazques G., Gual C., Perez-Palacios G. Pituitary LH and FSH secretion and responsiveness in women of old age. Acta Endocrinol. (Copenh.) 1976, 81:673-679.
59. Richardson S.J. The biological basis of the menopause. Baillier's clinical endocrinology and metabolism, vol. 7: The menopause 1993, 1-16. Baillere Tindall, Toronto. H.G. Burger (Ed.).
60. Zheng W.X., Magid M.S., Kramer E.E., Chen Y.T. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am. J. Pathol. 1996, 148:47-53.
61. Konishi I., Kuroda H., Mandai M. Review: Gonadotropins and development of ovarian cancer. Oncology 1999, 57(Suppl. 2):45-48.
62. Osterholzer H.O., Streibel E.J., Nicosia S.V. Growth effects of protein hormones on cultured rabbit ovarian surface epithelial cells. Biol. Reprod. 1985, 33:247-258.
63. Davies B.R., Finnigan D.S., Smith S.K., Ponder B.A. Administration of gonadotropins stimulates proliferation of normal mouse ovarian surface epithelium. Gynecol. Endocrinol. 1999, 13:75-81.
64. Wright J.W., Toth-Fejel S., Stouffer R.L., Rodland K.D. Proliferation of rhesus ovarian surface epithelial cells in culture: lack of mitogenic response to steroid or gonadotropic hormones. Endocrinology 2002, 143:2198-2207.
65. Kammerman S., Demopoulos R.I., Raphael C., Ross J. Gonadotropic hormone binding to human ovarian tumors. Hum. Pathol. 1981, 12:886-890.
66. Kobayashi F., Monma C., Nanbu K., Konishi I., Sagawa N., Mori T. Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Gynecol. Oncol. 1996, 62:309-313.
67. Mandai M., Konishi I., Kuroda H., Fukumoto M., Komatsu T., Yamamoto S., Nanbu K., Rao C.V., Mori T. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur. J. Cancer 1997, 33:1501-1507.
68. Emons G., Ortmann O., Pahwa G.S., Hackenberg R., Oberheuser F., Schulz K.D. Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Acta Obstet. Gynecol. Scand. Suppl. 1992, 155:31-38.
69. Godwin A.K., Perez R.P., Johnson S.W., Hamaguchi K., Hamilton T.C. Growth regulation of ovarian cancer. Hematol. Oncol. Clin. North Am. 1992, 6:829-841.
70. Wimalasena J., Dostal R., Meehan D. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol. Oncol. 1992, 46:345-350.
71. Kurbacher C.M., Jager W., Kurbacher J.A., Bittl A., Wildt L., Lang N. Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biol. 1995, 16:374-384.
72. Simon W.E., Albrecht M., Hansel M., Dietel M., Holzel F. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J. Natl. Cancer Inst. 1983, 70:839-845.
73. Kuroda H., Mandai M., Konishi I., Yura Y., Tsuruta Y., Hamid A.A., Nanbu K., Matsushita K., Mori T. Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of insulin-like growth factor-1 by hCG. Int. J. Cancer 1998, 76:571-578.
74. Schiffenbauer Y.S., Abramovitch R., Meir G., Nevo N., Holzinger M., Itin A., Keshet E., Neeman M. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc. Natl. Acad. Sci. USA 1997, 94:13203-13208.
75. Zheng W., Lu J.J., Luo F., Zheng Y., Feng Y., Felix J.C., Lauchlan S.C., Pike M.C. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol. Oncol. 2000, 76:80-88.
76. Choi K.C., Kang S.K., Tai C.J., Auersperg N., Leung P.C. Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 2002, 87:2245-2253.
77. Kang S.K., Choi K.C., Cheng K.W., Nathwani P.S., Auersperg N., Leung P.C. Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 2000, 141:72-80.
78. Choi K.C., Auersperg N., Leung P.C. Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 2001, 86:5075-5078.
79. Kim J.H., Park D.C., Kim J.W., Choi Y.K., Lew Y.O., Kim D.H., Jung J.K., Lim Y.A., Namkoong S.E. Antitumor effect of GnRH agonist in epithelial ovarian cancer. Gynecol. Oncol. 1999, 74:170-180.
80. Kimura A., Ohmichi M., Kurachi H., Ikegami H., Hayakawa J., Tasaka K., Kanda Y., Nishio Y., Jikihara H., Matsuura N., Murata Y. Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res. 1999, 59:5133-5142.
81. Peterson C.M., Jolles C.J., Carrell D.T., Straight R.C., Jones K.P., Poulson A.M.J., Hatasaka H.H. GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol. Oncol. 1994, 52:26-30.
82. Manetta A., Gamboa-Vujicic G., Paredes P., Emma D., Liao S., Leong L., Asch B., Schally A. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertil Steril 1995, 63:282-287.
83. Yano T., Pinski J., Halmos G., Szepeshazi K., Groot K., Schally A.V. Inhibition of growth of OV-1063 human epithelical ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc. Natl. Acad. Sci. USA 1994, 91:7090-7094.
84. Van der Vange N., Greggi S., Burger C.W., Kenemans P., Vermorken J.B. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol. 1995, 34:813-820.
85. Emons G., Ortmann O., Teichert H.M., Fassl H., Löhrs U., Kullander S., Kauppila A., Ayalon D., Schally A., Oberheuser F. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma: A prospective double blind randomized trial. Cancer 1996, 78:1452-1460.
86. Falkson C.I., Falkson H.C., Falkson G. Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: A pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin. Oncology 1996, 53:313-317.
87. Gondos B. Surface epithelium of the developing ovary. Possible correlation with ovarian neoplasia. Am. J. Pathol. 1975, 81:303-321.
88. Karlan B.Y., Jones J., Greenwald M., Lagasse L.D. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am. J. Obstet. Gynecol. 1995, 173:97-104.
89. Lau K.M., Mok S.C., Ho S.M. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc. Natl. Acad. Sci. USA 1999, 96:5722-5727.
90. Hamilton T.C., Davies P., Criffiths K. Steroid hormone receptor status of the normal and neoplastic ovarian surface germinal epithelium. Factors Regulating Ovarian Function 1983, 81-85. Raven Press, New York. G.S. Greenwald, P.F. Terranova (Eds.).
91. Murdoch W.J., Van Kirk E.A. Steroid hormonal regulation of proliferative, p53 tumor suppressor, and apoptotic responses of sheep ovarian surface epithelial cells. Mol. Cell Endocrinol. 2002, 186:61-67.
92. Bai W., Oliveros-Saunders B., Wang Q., Acevedo-Duncan M.E., Nicosia S.V. Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev. Biol. Anim. 2000, 36:657-666.
93. Lacey J.V., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., Schatzkin A., Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002, 288:334-341.
94. Kang S.K., Choi K.C., Tai C.J., Auersperg N., Leung P.C. Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. Endocrinology 2001, 142:580-588.
95. Liu Y., Lin L., Zarnegar R. Modulation of hepatocyte growth factor gene expression by estrogen in mouse ovary. Mol. Cell Endocrinol. 1994, 104:173-181.
96. Rodriguez G.C., Walmer D.K., Cline M., Krigman H., Lessey B.A., Whitaker R.S., Dodge R., Hughes C.L. Effect of progestin of the ovarian epithelium of macaques: Cancer prevention through apoptosis?. J. Soc. Gynecol. Investig. 1998, 5:271-276.
97. Adami H.O., Hsieh C.C., Lambe M., Trichopoulos D., Leon D., Persson I., Ekbom A., Janson P.O. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994, 344:1250-1254.
98. Kommoss F., Pfisterer J., Thome M., Schafer W., Sauerbrei W., Pfleiderer A. Steroid receptors in ovarian carcinoma: Immunohistochemical determination may lead to new aspects. Gynecol. Oncol. 1992, 47:317-322.99.
99. Brandenberger A.W., Tee M.K., Jaffe R.B. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: Down-regulation of ER-beta in neoplastic tissues. J. Clin. Endocrinol. Metab. 1998, 83:1025-1028.
100. Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., Whang-Peng J., Rogan A.M., Green W.R., Ozols R.F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983, 43:5379-5389.
101. Kuhnel R., de Graaff J., Rao B.R., Stolk J.G. Androgen receptor predominance in human ovarian carcinoma. J. Steroid Biochem. 1987, 26:393-397.
102. Grenman S.E., Klemi P., Toikkanen S., Kaihola H.L., Laippala P., Maenpaa J., Makinen J., Gronroos M. Steroid hormone receptors and flow cytometric DNA ploidy in ovarian carcinoma. Ann. Chir. Gynaecol. Suppl. 1994, 208:15-19.
103. Baldwin W.S., Curtis S.W., Cauthen C.A., Risinger J.I., Korach K.S., Barrett J.C. BG-1 ovarian cell line: An alternative model for examining estrogen-dependent growth in vitro. In Vitro Cell Dev. Biol. Anim. 1998, 34:649-654.
104. Vihko R., Isotalo H., Kauppila A., Vierikko P. Female sex steroid receptors in gynecological malignancies: Clinical correlates. J. Steroid Biochem. 1983, 19:827-832.
105. Iversen O.E., Skaarland E., Utaaker E. Steroid receptor content in human ovarian tumors: Survival of patients with ovarian carcinoma related to steroid receptor content. Gynecol. Oncol. 1986, 23:65-76.
106. Quinn M.A., Rome R.M., Cauchi M., Fortune D.W. Steroid receptors and ovarian tumors: Variation within primary tumors and between primary tumors and metastases. Gynecol. Oncol. 1988, 31:424-429.
107. Slotman B.J., Nauta J.J., Rao B.R. Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer 1990, 66:740-744.
108. Kieback D.G., McCamant S.K., Press M.F., Atkinson E.N., Gallager H.S., Edwards C.L., Hajek R.A., Jones L.A. Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor. Cancer Res. 1993, 53:5188-5192.
109. Nash J.D., Ozols R.F., Smyth J.F., Hamilton T.C. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet. Gynecol. 1989, 73:1009-1016.
110. Langdon S.P., Hawkes M.M., Lawrie S.S., Hawkins R.A., Tesdale A.L., Crew A.J., Miller W.R., Smyth J.F. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br. J. Cancer 1990, 62:213-216.
111. Langdon S.P., Ritchie A., Young K., Crew A.J., Sweeting V., Bramley T., Hillier S., Hawkins R.A., Tesdale A.L., Smyth J.F. Contrasting effects of 17 beta-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo. Int. J. Cancer 1993, 55:459-464.
112. Wimalasena J., Meehan D., Dostal R., Foster J.S., Cameron M., Smith M. Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol Res. 1993, 5:325-337.
113. Langdon S.P., Hirst G.L., Miller E.P., Hawkins R.A., Tesdale A.L., Smyth J.F., Miller W.R. The regulation of growth and protein expression by estrogen in vitro: A study of 8 human ovarian carcinoma cell lines. J. Steroid Biochem. Mol. Biol. 1994, 50:131-135.
114. Simpson B.J., Langdon S.P., Rabiasz G.J., Macleod K.G., Hirst G.L., Bartlett J.M., Crew A.J., Hawkins R.A., Macineira-Perez P.P., Smyth J.F., Miller W.R. Estrogen regulation of transforming growth factor-alpha in ovarian cancer. J. Steroid Biochem. Mol. Biol. 1998, 64:137-145.
115. Ridderheim M., Stendahl U., Backstrom T. Progesterone and estradiol stimulate release of epidermal growth factor/transforming growth factor alpha by ovarian tumours in vitro. Anticancer Res. 1994, 14:2763-2768.
116. Chien C.-H., Wang F.-F., Hamilton T.C. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol. Cell Endocrinol. 1994, 99:11-19.
117. Choi K.C., Kang S.K., Tai C.J., Auersperg N., Leung P.C. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 2001, 142:2351-2360.
118. Zachos G., Varras M., Koffa M., Ergazaki M., Spandidos D.A. Glucocorticoid and estrogen receptors have elevated activity in human endometrial and ovarian tumors as compared to the adjacent normal tissues and recognize sequence elements of the H-ras proto-oncogene. Jpn. J. Cancer Res. 1996, 87:916-922.
119. Bu S.Z., Yin D.L., Ren X.H., Jiang L.Z., Wu Z.J., Gao Q.R., Pei G. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997, 79:1944-1950.
120. Rao B.R., Slotman B.J. Endocrine factors in common epithelial ovarian cancer. Endocr. Rev. 1991, 12:14-26.
121. Heinonen P.K., Koivula T., Pystynen P. Elevated progesterone levels in serum and ovarian venous blood in patients with ovarian tumors. Acta Obstet. Gynecol. Scand. 1985, 64:649-652.
122. Abrahamsson G., Janson P.O., Kullander S. Steroid release from two human epithelial ovarian tumors: Evidence for an intrinsic production in vitro. Gynecol. Oncol. 1997, 64:99-104.
123. Okubo T., Mok S.C., Chen S. Regulation of aromatase expression in human ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 2000, 85:4889-4899.
124. Chadha S., Rao B.R., Slotman B.J., Van Vroonhoven C.C.J., Van der Kwast T.H. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum. Pathol. 1993, 24:90-95.
125. Ilekis J.V., Connor J.P., Prins G.S., Ferrer K., Niederberger C., Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol. Oncol. 1997, 66:250-254.
126. Adashi E.Y. The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fertil. Steril. 1994, 62:20-27.
127. Helzlsouer K.J., Alberg A.J., Gordon G.B., Longcope C., Bush T.L., Hoffman S.C., Comstock G.W. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995, 274:1926-1930.
128. Schildkraut J.M., Schwingl P.J., Bastos E., Evanoff A., Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet. Gynecol. 1996, 88:554-559.
129. Silva E.G., Tornos C., Fritsche H.A.J., el-Naggar A., Gray K., Ordonez N.G., Luna M., Gershenson D. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: A potential animal model. Mod. Pathol. 1997, 10:879-883.
130. Slotman B.J., Rao B.R. Response to inhibition of androgen action of human ovarian cancer cells in vitro. Cancer Lett. 1989, 45:213-220.
131. Edmondson R.J., Monaghan J.M., Davies B.R. The human ovarian surface epithelium is an androgen responsive tissue. Br. J. Cancer 2002, 86:879-885.
132. Evangelou A., Jindal S.K., Brown T.J., Letarte M. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res. 2000, 60:929-935.
133. Mintz B., Russell E.S. Gene-induced embryological modifications of primordial germ cells in the mouse. J. Exp. Zool. 1957, 134:207-237.
134. Murphy E.D. Hyperplastic and early neoplastic changes in the ovaries of mice after genic deletion of germ cells. J. Natl. Cancer Inst. 1972, 48:1283-1295.
135. Murphy E.D., Beamer W.G. Plasma gonadotropin levels during early stages of ovarian tumorigenesis in mice of the Wx/Wv genotype. Cancer Res. 1973, 33:721-723.
136. Ishimura K., Matsuda H., Tatsumi H., Fujita H., Terada N., Kitamura Y. Ultrastructural changes in the ovaries of Sl/Slt mutant mice, showing developmental deficiency of follicles and tubular adenomas. Arch. Histol. Jpn. 1986, 49:379-389.
137. Duncan M.K., Chada K.K. Incidence of tubulostromal adenoma of the ovary in aged germ cell-deficient mice. J. Comp. Pathol. 1993, 109:13-19.
138. Capen C.C., Beamer W.G., Tennent B.J., Stitzel K.A. Mechanisms of hormone-mediated carcinogenesis of the ovary in mice. Mutat. Res. 1995, 333:143-151.
139. Vanderhyden B.C., Caron P.J., Buccione R., Eppig J.J. Developmental pattern of the secretion of cumulus expansion-enabling factor by mouse oocytes and the role of oocytes in promoting granulosa cell differentiation. Dev. Biol. 1990, 140:307-317.
140. Vanderhyden B.C., Telfer E.E., Eppig J.J. Mouse oocytes promote proliferation of granulosa cells from preantral and antral follicles in vitro. Biol. Reprod. 1992, 46:1196-1204.
141. Dong J., Albertini D.F., Nishimori K., Kumar T.R., Lu N., Matzuk M.M. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature 1996, 383:531-535.
142. Teixeira Filho F.L., Baracat E.C., Lee T.H., Suh C.S., Matsui M., Chang R.J., Shimasaki S., Erickson G.F. Aberrant expression of growth differentiation factor-9 in oocytes of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2002, 87:1337-1344.
143. Tennent B.J., Beamer W.G. Ovarian tumors not induced by irradiation and gonadotropins in hypogonadal (hpg) mice. Biol. Reprod. 1986, 34:751-760.
144. Blaakaer J., Baeksted M., Micic S., Albrectsen P., Rygaard J., Bock J. Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Biol. Reprod. 1995, 53:775-779.
145. Cramer D.W., Muto M.G., Reichardt J.K., Xu H., Welch W.R., Valles B., Ng W.G. Characteristics of women with a family history of ovarian cancer. I. Galactose consumption and metabolism. Cancer 1994, 74:1309-1317.
146. Teinturier C., Hartmann O., Valteau-Couanet D., Benhamou E., Bougneres P.F. Ovarian function after autologous bone marrow transplantation in childhood: High-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant. 1998, 22:989-994.
147. Friedlander M.L. Prognostic factors in ovarian cancer. Semin. Oncol. 1998, 25:305-314.
148. Auersperg N., Edelson M.I., Mok S.C., Johnson S.W., Hamilton T.C. The biology of ovarian cancer. Semin. Oncol. 1998, 25:281-304.
149. Lynch H.T., Casey M.J., Lynch J., White T.E., Godwin A.K. Genetics and ovarian carcinoma. Semin. Oncol. 1998, 25:265-280.
150. Aunoble B., Sanches R., Didier E., Bignon Y.-J. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int. J. Oncol. 2000, 16:567-576.
151. Sklar M.D. Increased resistance to cis-diaminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res. 1988, 48:793-797.
152. Sklar M.D. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 1988, 239:645-647.
153. Scambia G., Masciullo V., Benedetti P.P., Marone M., Ferrandina G., Todaro N., Bellacosa A., Jain S.K., Neri G., Piffanelli A., Mancuso S. Prognostic significance of ras/p21 alterations in human ovarian cancer. Br. J. Cancer 1997, 75:1547-1553.
154. Hoffman A.G., Burghardt R.C., Tilley R., Auersperg N. An in vitro model of ovarian epithelial carcinogenesis: Changes in cell-cell communication and adhesion occuring during neoplastic progression. Int. J. Cancer 1993, 54:828-838.
155. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J.T., Dodge R., Clarke-Pearson D.L., Marks P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990, 50:4087-4091.
156. Gordon A.W., Pegues J.C., Johnson G.R., Kannan B., Auersperg N., Stromberg K. mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells. Cancer Lett. 1995, 89:63-71.
157. Ruler B.L., Carter D., Foellmer H.G., Kacinski B.M. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am. J. Pathol. 1992, 140:23-31.
158. Zheng J.P., Robinson W.R., Ehlen T., Yu M.C., Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res. 1991, 51:4045-4051.
159. Yu D.H., Liu B.L., Tan M., Li J.Z., Wang S.S., Hung M.C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996, 13:1359-1365.
160. Yu D., Wang S.S., Dulski K.M., Tsai C.M., Nicolson G.L., Hung M.C. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 1994, 54:3260-3266.
161. Davies B.R., Auersperg N., Worsley S.D., Ponder B.A. Transfection of rat ovarian surface epithelium with erb-B2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo. Am. J. Pathol. 1998, 152:297-306.
162. Yasue H., Takeda A., Ishibashi M. Amplification of the c-myc gene and the elevation of its transcripts in human ovarian tumor lines. Cell Struct. Funct. 1987, 12:121-125.
163. Tashiro H., Miyazaki K., Okamura H., Iwai A., Fukumoto M. c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression. Int. J. Cancer 1992, 50:828-833.
164. Katsaros D., Theillet C., Zola P., Louason G., Sanfilippo B., Isaia E., Arisio R., Giardina G., Sismondi P. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res 1995, 15:1501-1510.
165. Scully R., Chen J., Plug A., Xiao Y., Weaver D., Feunteun J., Ashley T., Livingston D.M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997, 88:265-275.
166. Chen J.J., Silver D., Cantor S., Livingston D.M., Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 1999, 59:1752s-1756s.
167. Scully R., Anderson S.F., Chao D.M., Wei W., Ye L., Young R.A., Livingston D.M., Parvin J.D. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc. Natl. Acad. Sci. USA 1997, 94:5605-5610.
168. Holt J.T., Thompson M.E., Szabo C., Robinson-Benion C., Arteaga C.L., King M.C., Jensen R.A. Growth retardation and tumour inhibition by BRCA1. Nat. Genet. 1996, 12:298-302.
169. Narod S.A., Ford D., Devilee P., Barkardottir R.B., Lynch H.T., Smith S.A., Ponder B.A.J., Weber B.L., Garber J.E., Birch J.M., Cornelis R.S., Kelsell D.P., Spurr N.K., Smyth E., Haites N., Sobol H., Bignon Y.-J., Chang-Claude J., Hamann U., Lindblom A., Borg A., Piver M.S., Gallion H.H., Struewing J.P. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am. J. Hum. Genet. 1995, 56:254-264.
170. Futreal P.A., Liu Q., Shattuck-Eidens D., Cochran C., Harshman K., Tavtigian S., Bennett L.M., Haugen-Strano A., Swensen J., Miki Y., Eddington K., McClure M., Frye C., Weaver-Feldhaus J., Ding W., Gholami Z., Söderkvist P., Terry L., Jhanwar S., Berchuck A., Iglehart J.D., Marks J., Ballinger D.G., Barrett J.C., Skolnick M.H., Kamb A., Wiseman R. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994, 266:120-122.
171. Merajver S.D., Pham T.M., Caduff R.F., Chen M., Poy E.L., Cooney KA., Weber B.L., Collins F.S., Johnston C., Frank T.S. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet. 1995, 9:439-443.
172. Takahashi H., Behbakht K., McGovern P.E., Chiu H.-C., Couch F.J., Weber B.L., Friedman L.S., King M.-C., Furusato M., LiVolsi V.A., Menzin A.W., Liu P.C., Benjamin I., Morgan M.A., King S.A., Rebane B.A., Cardonick A., Mikuta J.J., Rubin S.C., Boyd J. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 1995, 55:2998-3002.
173. Pharoah P.D., Easton D.F., Stockton D.L., Gayther S., Ponder B.A. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res. 1999, 59:868-871.
174. Foster K.A., Harrington P., Kerr J., Russell P., DiCioccio R.A., Scott I.V., Jacobs I., Chenevix-Trench G., Ponder B.A.J., Gayther S.A. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res. 1996, 56:3622-3625.
175. Runnebaum I.B., Tong X.W., Konig R., Zhao H., Korner K., Atkinson E.N., Kreienberg R., Kieback D.G., Hong Z. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet 1995, 345:994.
176. Takahashi H., Chiu H.C., Bandera C.A., Behbakht K., Liu P.C., Couch F.J., Weber B.L., LiVolsi V.A., Furusato M., Rebane B.A., Cardonick A., Benjamin I., Morgan M.A., King S.A., Mikuta J.J., Rubin S.C., Boyd J. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res. 1996, 56:2738-2741.
177. Santoso J.T., Tang D.C., Lane S.B., Hung J., Reed D.J., Muller C.Y., Carbone D.P., Lucci J.A., Miller D.S., Mathis J.M. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol. Oncol. 1995, 59:171-178.
178. Mujoo K., Maneval D.C., Anderson S.C., Gutterman J.U. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996, 12:1617-1623.
179. Gallardo D., Drazan K.E., McBride W.H. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res. 1996, 56:4891-4893.
180. Nielsen L.L., Lipari P., Dell J., Gurnani M., Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 1998, 4:835-846.
181. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix-Trench G., Thomas E.J., Campbell I.G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998, 58:2095-2097.
182. Yu Y., Xu F., Peng H., Fang X., Zhao S., Li Y., Cuevas B., Kuo W.L., Gray J.W., Siciliano M., Mills G.B., Bast R.C. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. USA 1999, 96:214-219.
183. Fazili Z., Sun W., Mittelstaedt S., Cohen C., Xu X.X. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 1999, 18:3104-3113.
184. Mok S.C., Chan W.Y., Wong K.K., Cheung K.K., Lau C.C., Ng S.W., Baldini A., Colitti C.V., Rock C.O., Berkowitz R.S. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998, 16:2381-2387.
185. Tong X.W., Kieback D.G., Ramesh R., Freeman S.M. Molecular aspects of ovarian cancer. Is gene therapy the solution?. Hematol. Oncol. Clin. North Am. 1999, 13:109-133.
186. Berchuck A., Rodriguez G.C., Kamel A., Dodge R.K., Soper J.T., Clarke-Pearson D.L., Bast R.C. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol. 1991, 164:669-674.
187. Siemens C.H., Auersperg N. Serial propagation of human ovarian surface epithelium in tissue culture. J. Cell Physiol. 1988, 134:347-356.
188. Salomon D.S., Kim N., Saeki T., Ciardiello F. Transforming growth factor-alpha: An oncodevelopmental growth factor. Cancer Cells 1990, 2:389-397.
189. Jindal S.K., Snoey D.M., Lobb D.K., Dorrington J.H. Transforming growth factor-α localization and role in surface epithelium of normal human ovaries and in ovarian carcinoma cells. Gynecol. Oncol. 1994, 53:17-23.
190. Stromberg K., Collins T.J., Gordon A.W., Jackson C.L., Johnson G.R. Transforming growth factor-α acts as an autocrine growth factor in ovarian carcinoma cell lines. Cancer Res. 1992, 52:341-347.
191. Marth C., Lang T., Cronauer M.V., Doppler W., Zeimet A.G., Bachmair F., Ullrich A., Daxenbichler G. Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells. Int. J. Cancer 1992, 52:311-316.
192. Park H.Y. Inhibition of the proliferative effect of transforming growth factor-alpha by c-myc antisense DNA in human ovarian cancer cells. Biochem. Mol. Biol. Int. 1997, 43:1015-1022.
193. Baekelandt M., Kristensen G.B., Trope C.G., Nesland J.M., Holm R. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res. 1999, 19:4469-4474.
194. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 1999, 21:99-102.
195. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Panici P.B., Mancuso S., Neri G., Testa J.R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 1995, 22:280-285.
196. Wong A.S., Kim S.O., Leung P.C., Auersperg N., Pelech S.L. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol. Oncol. 2001, 82:305-311.
197. Lyons R.M., Moses H.L. Transforming growth factors and the regulation of cell proliferation. Eur. J. Biochem 1990, 187:467-473.
198. Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P., Arrick B.A., Clarke-Pearson D.L., Bast R.C. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β. Am. J. Obstet. Gynecol. 1992, 166:676-684.
199. Havrilesky L.J., Hurteau J.A., Whitaker R.S., Elbendary A., Wu S., Rodriguez G.C., Bast R.C., Berchuck A. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β. Cancer Res. 1995, 55:944-948.
200. Hurteau J., Rodriguez G.C., Whitaker R.S., Shah S., Mills G., Bast R.C., Berchuck A. Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 1994, 74:93-99.
201. Kim J.W., Lee C.G., Lyu M.S., Kim H.K., Rha J.G., Kim D.H., Kim S.J., Namkoong S.E. A new cell line from human undifferentiated carcinoma of the ovary: Establishment and characterization. J. Cancer Res. Clin. Oncol. 1997, 123:82-90.
202. Lafon C., Mathieu C., Guerrin M., Pierre O., Vidal S., Valette A. Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: Protection by the antioxidant N-acetylcysteine and bcl-2. Cell. Growth Differ. 1996, 7:1095-1104.
203. Dunfield L.D., Dwyer E.J., Nachtigal M.W. TGF beta-induced Smad signaling remains intact in primary human ovarian cancer cells. Endocrinology 2002, 143:1174-1181.
204. Ziltener H.J., Maines-Bandiera S., Schrader J.W., Auersperg N. Secretion of bioactive interleukin-1, interleukin-6, and colony-stimulating factors by human ovarian surface epithelium. Biol. Reprod. 1993, 49:635-641.
205. Ismail R.S., Cada M., Vanderhyden B.C. Transforming growth factor-beta regulates Kit ligand expression in rat ovarian surface epithelial cells. Oncogene 1999, 18:4734-4741.
206. Tonary A.M., Macdonald E.A., Faught W., Senterman M.K., Vanderhyden B.C. Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int. J. Cancer 2000, 89:242-250.
207. Parrott J.A., Kim G., Skinner M.K. Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol. Reprod. 2000, 62:1600-1609.
208. Berchuck A., Kohler M.F., Boente M.P., Rodriguez G.C., Whitaker R.S., Bast R.C. Growth regulation and transformation of ovarian epithelium. Cancer 1993, 71:545-551. (Suppl.).
209. Chambers S.K., Wang Y., Gertz R.E., Kacinski B.M. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res. 1995, 55:1578-1585.
210. Huntsman D., Resau J.H., Klineberg E., Auersperg N. Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am. J. Pathol. 1999, 155:343-348.
211. Parrott J.A., Skinner M.K. Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer. Biol. Reprod. 2000, 62:491-500.
212. Hess S., Gulati R., Peluso J.J. Hepatocyte growth factor induces rat ovarian surface epithelial cell mitosis or apoptosis depending on the presence or absence of an extracellular matrix. Endocrinology 1999, 140:2908-2916.
213. Di Renzo M.F., Olivero M., Katsaros D., Crepaldi T., Gaglia P., Zola P., Sismondi P., Comoglio P.M. Overexpression of the Met/HGF receptor in ovarian cancer. Int. J. Cancer 1994, 58:658-662.
214. Corps A.N., Sowter H.M., Smith S.K. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int. J. Cancer 1997, 73:151-155.
215. Ueoka Y., Kato K., Kuriaki Y., Horiuchi S., Terao Y., Nishida J., Ueno H., Wake N. Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via Ras-mediated pathway. Br. J. Cancer 2000, 82:891-899.
216. Shu X.O., Gao Y.T., Yuan J.M., Ziegler R.G., Brinton L.A Dietary factors and epithelial ovarian cancer. Br. J. Cancer 1989, 59:92-96.
217. Gertig D.M., Hunter D.J., Cramer D.W., Colditz G.A., Speizer F.E., Willett W.C., Hankinson S.E. Prospective study of talc use and ovarian cancer. J. Natl. Cancer Inst. 2000, 92:249-252.
218. Hamilton T.C., Fox H., Buckley C.H., Henderson W.J., Griffiths K. Effects of talc on the rat ovary. Br. J. Exp. Pathol. 1984, 65:101-106.
219. Menczer J., Modan M., Ranon L., Golan A. Possible role of mumps virus in the etiology of ovarian cancer. Cancer 1979, 43:1375-1379.
220. Hardiman P., Nieto J.J., MacLean A.B. Infertility and ovarian cancer. Gynecol. Oncol. 1999, 76:1-2.
221. Modugno F., Ness R.B., Cottreau C.M. Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology 2002, 13:467-471.
222. Iatropoulos M.J., Hobson W., Knauf V., Adams H.P. Morphological effects of hexachlorobenzene toxicity in female rhesus monkeys. Toxicol. Appl. Pharmacol. 1976, 37:433-444.
223. Babineau K.A., Singh A., Jarrell J.F., Villeneuve D.C. Surface epithelium of the ovary following oral administration of hexachlorobenzene to the monkey. J. Submicrosc. Cytol. Pathol. 1991, 23:457-464.
224. Sims D.E., Singh A., Donald A., Jarrell J., Villeneuve D.C. Alteration of primate ovary surface epithelium by exposure to hexachlorobenzene: A quantitative study. Histol. Histopathol. 1991, 6:525-529.
225. Borgeest C., Symonds D., Mayer L.P., Hoyer P.B., Flaws J.A. Methoxychlor may cause ovarian follicular atresia and proliferation of the ovarian epithelium in the mouse. Toxicol. Sci. 2002, 68:473-478.
226. Ness R.B., Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl. Cancer Inst. 1999, 91:1459-1467.
227. Ness R.B., Grisso J.A., Cottreau C., Klapper J., Vergona R., Wheeler J.E., Morgan M., Schlesselman J.J. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000, 11:111-117.
228. Negus R.P., Stamp G.W., Relf M.G., Burke F., Malik S.T., Bernasconi S., Allavena P., Sozzani S., Mantovani A., Balkwill F.R. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest. 1995, 95:2391-2396.
229. Naylor M.S., Stamp G.W., Foulkes W.D., Eccles D., Balkwill F.R. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J. Clin. Invest. 1993, 91:2194-2206.
230. van Niekerk C.C., Ramaekers F.C., Hanselaar A.G., Aldeweireldt J., Poels L.G. Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am. J. Pathol. 1993, 142:157-177.
231. Auersperg N., Siemens C.H., Myrdal S.E. Human ovarian surface epithelium in primary culture. In Vitro 1984, 20:743-755.
232. van Niekerk C.C., Jap P.H., Thomas C.M., Smeets D.F., Ramaekers F.C., Poels L.G. Marker profile of mesothelial cells versus ovarian carcinoma cells. Int. J. Cancer 1989, 43:1065-1071.
233. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr. Rev. 2001, 22:255-288.
234. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes?. Gynecol. Oncol. 1999, 72:437-442.
235. Sundfeldt K., Piontkewitz Y., Ivarsson K., Nilsson O., Hellberg P., Brännström M., Janson P.O., Enerback S., Hedin L. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int. J. Cancer 1997, 74:275-280.
236. Wang D.P., Konishi I., Koshiyama M., Nanbu Y., Iwai T., Nonogaki H., Mori T., Fujii S. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. Virchows. Arch. A. Pathol. Anat. Histopathol. 1992, 421:393-400.
237. Naora H., Montz F.J., Chai C.Y., Roden R.B. Aberrant expression of homeobox gene HOXA7 is associated with mullerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proc. Natl. Acad. Sci. USA 2001, 98:15209-15214.
238. Maines-Bandiera S.L., Auersperg N. Increased E-cadherin expression in ovarian surface epithelium: An early step in metaplasia and dysplasia?. Int. J. Gynecol. Pathol. 1997, 16:250-255.
239. Auersperg N., Maines-Bandiera S.L., Dyck H.G., Kruk P.A. Characterization of cultured human ovarian surface epithelial cells: Phenotypic plasticity and premalignant changes. Lab. Invest. 1994, 71:510-518.
240. Auersperg N., Maines-Bandiera S., Booth J.H., Lynch H.T., Godwin A.K., Hamilton T.C. Expression of two mucin antigens in cultured human ovarian surface epithelium: Influence of a family history of ovarian cancer. Am. J. Obstet. Gynecol. 1995, 173:558-565.
241. Dyck H.G., Hamilton T.C., Godwin A.K., Lynch H.T., Maines-Bandiera S., Auersperg N. Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer. Int. J. Cancer 1996, 69:429-436.
242. Wong A.S., Maines-Bandiera S.L., Rosen B., Wheelock M.J., Johnson K.R., Leung P.C., Roskelley C.D., Auersperg N. Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: Influence of family history of ovarian cancer. Int. J. Cancer 1999, 81:180-188.
243. Auersperg N., Pan J., Grove B.D., Peterson T., Fisher J., Maines-Bandiera S., Somasiri A., Roskelley C.D. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc. Natl. Acad. Sci. USA 1999, 96:6249-6254.
244. Ong A., Maines-Bandiera S.L., Roskelley C.D., Auersperg N. An ovarian adenocarcinoma line derived from SV40/E-cadherin-transfected normal human ovarian surface epithelium. Int. J. Cancer 2000, 85:430-437.
245. Leung E.H., Leung P.C., Auersperg N. Differentiation and growth potential of human ovarian surface epithelial cells expressing temperature-sensitive SV40 T antigen. In Vitro Cell Dev. Biol. Anim. 2001, 37:515-521.
246. Gregoire L., Rabah R., Schmelz E.M., Munkarah A., Roberts P.C., Lancaster W.D. Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro. Clin. Cancer Res. 2001, 7:4280-4287.
247. Adams A.T., Auersperg N. A cell line, ROSE 199, derived from normal rat ovarian surface epithelium. Exp. Cell Biol. 1985, 53:181-188.
248. Orsulic S., Li Y., Soslow R.A., Vitale-Cross L.A., Gutkind J.S., Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002, 1:53-62.
249. Tonin P.N., Hudson T.J., Rodier F., Bossolasco M., Lee P.D., Novak J., Manderson E.N., Provencher D., Mes-Masson A.M. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001, 20:6617-6626.
250. Roberts D., Williams S.J., Cvetkovic D., Weinstein J.K., Godwin A.K., Johnson S.W., Hamilton T.C. Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA Cell Biol. 2002, 21:11-19.
251. Ono K., Tanaka T., Tsunoda T., Kitahara O., Kihara C., Okamoto A., Ochiai K., Takagi T., Nakamura Y. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 2000, 60:5007-5011.
252. Biskind M.S., Biskind G.S. Development of tumors in the rat ovary after transplantation into the spleen. Proc. Soc. Exp. Biol. Med. 1944, 55:176-179.
253. Matzuk M.M., Finegold M.J., Su J.G., Hsueh A.J., Bradley A. Alpha-inhibin is a tumor-suppressor gene with gonadal specificity in mice. Nature 1992, 360:313-319.
254. Nilson J.H., Abbud R.A., Keri R.A., Quirk C.C. Chronic hypersecretion of luteinizing hormone in transgenic mice disrupts both ovarian and pituitary function, with some effects modified by the genetic background. Recent Prog. Horm. Res. 2000, 55:69-89.
255. Keri R.A., Lozada K.L., Abdul-Karim F.W., Nadeau J.H., Nilson J.H. Luteinizing hormone induction of ovarian tumors: Oligogenic differences between mouse strains dictates tumor disposition. Proc. Natl. Acad. Sci. USA 2000, 97:383-387.
256. Danilovich N., Roy I., Sairam M.R. Ovarian pathology and high incidence of sex cord tumors in follitropin receptor knockout (FORKO) mice. Endocrinology 2001, 142:3673-3684.
257. Kananen K., Markkula M., Rainio E., Su J.G., Hsueh A.J., Huhtaniemi I.T. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: Characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol. Endocrinol. 1995, 9:616-627.
258. Dutertre M., Gouedard L., Xavier F., Long W.Q., di Clemente N., Picard J.Y., Rey R. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology 2001, 142:4040-4046.
259. Ward B.G., Wallace K. Localization of the monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts. Cancer Res. 1987, 47:4714-4718.
260. Hamilton T.C., Young R.C., Louie K.G., Behrens B.C., McKoy W.M., Grotzinger K.R., Ozols R.F. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 1984, 44:5286-5290.
261. Massazza G., Tomasoni A., Lucchini V., Allavena P., Erba E., Colombo N., Mantovani A., D'Incalci M., Mangioni C., Giavazzi R. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int. J. Cancer 1989, 44:494-500.
262. Lee W.S., Otsuka F., Moore R.K., Shimasaki S. Effect of bone morphogenetic protein-7 on folliculogenesis and ovulation in the rat. Biol. Reprod. 2001, 65:994-999.
263. Van der Hoek K.H., Maddocks S., Woodhouse C.M., van Rooijen N., Robertson S.A., Norman R.J. Intrabursal injection of clodronate liposomes causes macrophage depletion and inhibits ovulation in the mouse ovary. Biol. Reprod. 2000, 62:1059-1066.
264. Sato M., Kimura M. Intrabursal transfer of spermatozoa (TS): A new route for artificial insemination of mice. Theriogenology 2001, 55:1881-1890.
265. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1998. CA Cancer J. Clin. 1998, 48:6-29.
266. Collins W.P., Bourne T.H., Campbell S. Screening strategies for ovarian cancer. Curr. Opin. Obstet. Gynecol. 1998, 10:33-39.